Status:
RECRUITING
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Autoimmune Encephalitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute...
Detailed Description
Autoimmune encephalitis is a diagnostic challenge, and requires early diagnosis for improved neurological outcomes. FDG PET has shown very high sensitivity, suggesting better performances than MRI, bu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age ≥ 18 years old
- Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria :
- " Definite limbic autoimmune encephalitis " according to 2016 Graus et al. criteria
- " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF
- " Probable or certain paraneoplastic neurological syndrome " according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes)
- Less than 6 months since first neurological symptoms imputable to autoimmune encephalitis
- Affiliated or entitled to a social security system (except AME)
- Obtaining free, written and informed consent (patient or legal representative or the close relative)
- Exclusion criteria
- History of brain tumor, head trauma, infarction or cerebral hematoma likely to result in altered cerebral carbohydrate metabolism on PET
- Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exchange, endoxan, rituximab or other immunotherapy) fr more than 10 days
- Pregnant or breast-feeding woman
- Ventilated intubated patient
- Absolute contraindication to MRI (Pacemaker, cochlear implant, etc.)
- Presence of cognitive disorders incompatible with goog cooperation with the PET scan
- Algic or agitated patient unable to remain immobile in supine position for 30 minutes
- Deprived of liberty or under a protective measure (guardianship or curatorship)
- Patient taking part in other interventional research involving radiopharmaceutical injections
Exclusion
Key Trial Info
Start Date :
May 31 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06079294
Start Date
May 31 2024
End Date
May 31 2026
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Pitie Salpetriere
Paris, France, 75013